NCT
HOME CURRENT ARCHIVE COVID-19
HOME CURRENT ARCHIVE PUBLISH INSTRUCTIONS
FOR AUTHORS COVID-19 LOG IN / REGISTER HISTORY ABOUT US DIRECTORY CONTACT
Pulmonary surfactant exogenous in adults with acute respiratory distress syndrome

Barrese-Pérez, Yinet; Hidalgo-Sánchez, Angela Olga; Ávila-Albuerne, Yisel; Uranga-Piña, Rolando; Díaz-Casañas, Elaine; Fernández-Limia, Octavio





2015, Number 3

2015; 74 (3)






ABSTRACT

Objective: To determine the effect of the lung surfactant (Surfacen®) in the recovery of the oxygenation in adults with acute respiratory distress syndrome (ARDS). Material and methods: Adults between 18 and 75 years with acute respiratory distress syndrome, were included (48 patients) in a clinical trial phase II, controlled, randomized and multicentric. A group (24) received treatment of lung surfactant every eight hours, during three days, in dose of 100 total mg, next to the standard treatment (oxygenation and ventilation mechanics). The group control (24) alone received the standard treatment. The effect was evaluated through the index PaO2/FiO2, compliance (Cs) and the thorax X-Ray. Other studied variables were the mortality, days of intubation, of ventilation mechanics (VM) and of stay in the Unit of Intensive Cares (UCI). Results: It existed differences statistically significant (p=0.0399) among the groups in the index PaO2/FiO2, compliance (p = 0.005). There were not statistical differences in the thorax X-Ray (p = 0.7177), the mortality (p = 0.3652), days of intubation endotracheal (p = 0.2659), of ventilation mechanics (p = 0.3582) and stay in the UCI (p = 0.2941). Conclusions: The use of the lung surfactant (Surfacen®) next to the standard treatment in adults with ARDS improved oxygenation significantly

KEYWORDS

Exogenous surfactant, acute respiratory distress syndrome, adults.

REFERENCES

  1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;2(7511):319-323.

  2. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149(3 Pt 1):818-824.

  3. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307(23):2526-2533. doi: 10.1001/jama.2012.5669.

  4. Costa EL, Amato MB. The new definition for acute lung injury and acute respiratory distress syndrome: is there room for improvement? Curr Opin Crit Care 2013;19(1):16-23. doi: 10.1097/MCC.0b013e32835c50b1.

  5. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 2013;41(5):1167-1174. doi: 10.1097/CCM.0b013e31827c09f8.

  6. Goyal M, Houseman D, Johnson NJ, Christie J, Mikkelsen ME, Gaieski DF. Prevalence of acute lung injury among medical patients in the emergency department. Acad Emerg Med 2012;19(9):E1011-1018. doi: 10.1111/j.1553-2712.2012.01429.x.

  7. Mikkelsen ME, Shah CV, Meyer NJ, et al. The epidemiology of acute respiratory distress syndrome in patients presenting to the emergency department with severe sepsis. Shock 2013;40(5):375-381. doi: 10.1097/SHK.0b013e3182a64682.

  8. Villar J, Blanco J, Kacmarek RM. Acute respiratory distress syndrome definition: do we need a change? Curr Opin Crit Care 2011;17(1):13-17. doi: 10.1097/MCC.0b013e32834271fb.

  9. Saharan S, Lodha R, Kabra SK. Management of acute lung injury/ARDS. Indian J Pediatr 2010;77(11):1296-302. doi: 10.1007/s12098-010-0169-z.

  10. Raghavendran K, Willson D, Notter RH. Surfactant therapy for acute lung injury and acute respiratory distress syndrome. Crit Care Clin 2011;27(3):525-559. doi: 10.1016/j.ccc.2011.04.005.

  11. Manzanares TD, Díaz CE, Alfonso Lorenzo WC, et al. Centro Nacional de Sanidad Agropecuaria. Surfactante pulmonar natural de origen porcino. Patente de la República de Cuba A61K 35/42. 1997 Dic 24.

  12. Kesecioglu J, Beale R, Stewart TE, et al. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2009;180(10):989-994. doi: 10.1164/rccm.200812-1955OC.

  13. Brown LM, Kallet RH, Matthay MA, Dicker RA. The influence of race on the development of acute lung injury in trauma patients. Am J Surg 2011;201(4):486-491. doi: 10.1016/j.amjsurg.2010.02.003.

  14. Spragg RG, Lewis JF, Wurst W, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003;167(11):1562-1566.

  15. Willson DF, Thomas NJ, Markovitz BP, et al.; Pediatric Acute Lung Injury and Sepsis Investigators. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005;293(4):470-476.

  16. Amital A, Shitrit D, Raviv Y, et al. The use of surfactant in lung transplantation. Transplantation 2008;86(11):1554-1559. doi: 10.1097/TP.0b013e31818a8418.

  17. Taut FJ, Rippin G, Schenk P, et al. A Search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). Chest 2008;134(4):724-732. doi: 10.1378/chest.08-0362.

  18. Delfín BCA, Rodríguez ÁA. Administración del surfactante exógeno en el síndrome de distress respiratorio agudo. Rev Cub Med Int Emerg 2005;5(1):1-13.

  19. Sánchez RC, Torres TJ. Surfactante pulmonar. Rev Ped Elec (en línea) 2004;1(1):45-50. ISSN 0718-0918

  20. Rodríguez MVS, Prince MIA, Loret de Mola BY, Díaz CE. Uso de surfactante exógeno en un caso pediátrico de insuficiencia respiratoria aguda hipoxémica: presentación de un caso. AMC [revista en línea]. 2014;18(1):100-109. Fecha de consulta: 22 de febrero, 2015. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552014000100011&lng=es.

  21. Villar J, Blanco J, Añón JM, et al.; ALIEN Network. The ALIEN study: Incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med 2011;37(12):1932-1941. doi: 10.1007/s00134-011-2380-4.

  22. Kesecioglu J, Schultz M, Lundberg D, Lauven P, Lachmann B. Treatment of acute lung injury (ALI/ARDS) with surfactant [abstract]. Am J Respir Crit Care Med 2001;163:A819.

  23. Kesecioglu J, Schultz M, Maas J, De Wilde R, Steenken E, Lachmann B. Treatment of acute lung injury and ARDS with surfactant is safe [abstract]. Am J Respir Crit Care Med 2004;169:A349.

  24. Willson DF, Thomas NJ, Tamburro R, et al.; Pediatric Acute Lung and Sepsis Investigators Network. Pediatric calfactant in acute respiratory distress syndrome trial. Pediatr Crit Care Med 2013;14(7):657-665. doi: 10.1097/PCC.0b013e3182917b68.


2015, Number 3

2015; 74 (3)